Literature DB >> 19441090

Leiomyosarcoma of the larynx as a local relapse of squamous cell carcinoma--report of an unusual case.

Hans-Ullrich Völker1, Andreas Zettl, Eugenia Haralambieva, Bernd Blume, Rudolf Hagen, Hans-Konrad Müller-Hermelink, Matthias Scheich.   

Abstract

BACKGROUND: The authors report on leiomyosarcoma after previously treated squamous cell carcinoma (SCC) at the glottis.
METHODS: Primary tumor and relapses were investigated morphologically, immunohistochemically, and with molecular methods.
RESULTS: The SCC was typical, but few cells showed a spindle-shaped pattern. The relapse tumor was a spindle-shaped and epitheloid tumor with the morphological and immunohistochemical appearance of leiomyosarcoma (sm-actin+, desmin+, caldesmon+, vimentin+, keratin-).The comparative genomic hybridization (CGH) revealed some gains and losses in the leiomyosarcoma. Because of altered material, the investigation failed in the primary. A fluorescence in situ hybridization (5p) focally detected 3 chromosmomal copies, corresponding to gains on 5p in CGH of leiomyosarcoma.
CONCLUSION: Leiomyosarcoma after SCC is very uncommon. A connection between both seems likely in this case. Transdifferentiation, also seen in other tumors or carcinosarcomas, could be based on aberrant differentiation of a pluripotent stem cell.

Entities:  

Mesh:

Year:  2010        PMID: 19441090     DOI: 10.1002/hed.21127

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  Leiomyosarcoma of the Penis: A Case Report and Re-Appraisal.

Authors:  Zainub Ajmal; Abdul Moiz Khan; Fatima Tuz Zahra; Lezah McCarthy; Rebecca O'Malley; Syed Mehdi
Journal:  Fed Pract       Date:  2022-05-13

2.  Kissing tumors; the concurrent diagnosis of leiomyosarcoma and squamous cell carcinoma of the esophagus.

Authors:  Hamed Gheibollahi; Amirreza Dehghanian; Negar Taheri; Saeid Tavanafar; Seyede Sona Mousavi; Hamidreza Abbasi; Mohammadreza Sasani
Journal:  BMC Surg       Date:  2021-01-06       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.